BioLineRx (NASDAQ:BLRX) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Shares of BioLineRx Ltd. (NASDAQ:BLRX) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.87 and traded as high as $3.29. BioLineRx shares last traded at $3.16, with a volume of 6,025 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioLineRx in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

BioLineRx Price Performance

The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.43 and a current ratio of 1.58. The company has a 50-day moving average of $3.02 and a 200-day moving average of $2.87. The firm has a market capitalization of $13.81 million, a price-to-earnings ratio of -1.65 and a beta of 1.53.

BioLineRx (NASDAQ:BLRX) last announced its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.68. BioLineRx had a negative net margin of 563.70% and a negative return on equity of 37.73%. The firm had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.34 million.

About BioLineRx

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.